TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from OptiBiotix Health ( (GB:OPTI) ) is now available.
OptiBiotix Health plc announced the publication of a new study on its product SlimBiome® in the European Journal of Nutrition. The study, led by Professor Adele Costabile, found that a single dose of SlimBiome® significantly reduced insulin levels, hunger, and the desire to eat while increasing fullness, highlighting its potential as a non-pharmaceutical weight management solution. These findings support health claims for appetite regulation and differentiate SlimBiome® from other market products. The study’s results align with consumer feedback and previous studies, indicating SlimBiome®’s effectiveness in sustainable weight management. This development positions OptiBiotix favorably in the evolving weight management market, which is increasingly favoring science-backed products over traditional methods.
More about OptiBiotix Health
OptiBiotix Health plc, founded in March 2012, is a life sciences company focused on developing compounds that modify the human microbiome to prevent and manage diseases and promote wellness. The company has an extensive R&D program and collaborates with international food and healthcare supplement companies to incorporate its microbiome modulators into various products. OptiBiotix is also developing its own range of consumer supplements and health products, focusing on obesity, cardiovascular health, and diabetes.
Average Trading Volume: 400,956
Technical Sentiment Signal: Strong Sell
Current Market Cap: £13.17M
Find detailed analytics on OPTI stock on TipRanks’ Stock Analysis page.